Derivatives of betulin

A compound having the structure of Formula I:

• or a pharmaceutically acceptable salt thereof, wherein:
• A is
• L1 and L2 are [C(R6R6′)]q;
• each Q is independently selected from—CH2— or —C(═O)—;
• W is selected from a bond or O;
• R1 is selected from the group consisting of —H, (C1-C6)alkyl, —C(O)R4, and
• R2 is selected from the group consisting of —H, (C1-C6)alkyl, —(C1-C6)alkyl-OR4, —(C1-C6)alkyl-O—(C1-C6)alkyl, —C(O)R5, and —(CH2)rNR7R8, and —(CH2)rN+(R4)3;
• R3 is selected from the group consisting of —H, (C1-C12)alkyl, —NR1R2, —OR5,
• wherein:
• X is a monocyclic or bicyclic (C5-C14)aryl,
• Y is selected from a monocyclic or bicyclic (C2-C9)heterocyclyl or monocyclic or bicyclic (C2-C9)heteroaryl, each having one to three heteroatoms selected from S, N or O, and
• Z is a monocyclic or bicyclic (C3-C8)cycloalkyl;
• R4 is selected from the group consisting of —H and (C1-C6)alkyl;
• R5 is selected from the group consisting of (C1-C6)alkyl, —(CH2)rNR7R8, and —(CH2)rOR7;
• R6 and R6′ are independently selected from the group consisting of —H, (C1-C6)alkyl, (C3-C8)cycloalkyl, (C1-C6)alkoxy, haloalkyl, —(CH2)rNR7R8, —C(O)OH, and —C(O)NH2, wherein the R6 and R6′ groups can optionally be taken together with the carbon to which they are joined to form a 3 to 8 membered cycloalkyl ring, and wherein the cycloalkyl ring may be optionally substituted by one to three R11 groups;
• R7 and R8 are independently selected from the group consisting of —H, (C1-C6)alkyl, (C3-C8)cycloalkyl, —NR14R15, and —C(O)CH3;
• R9 is halo;
• R10 is —N(R16)2;
• R11, R12, and R13 are independently selected from the group consisting of oxo, hydroxyl, halo, (C1-C6)alkoxy, —R6(R9)q, —OR6(R9)q, nitro, —SO2R6, (C1-C6)alkyl, —C(O)R10, —R4YR6, —CO(O)R4, and —CO(O)R5;
• R14 and R15 are independently selected from the group consisting of —H, (C1—C—6)alkyl, (C3-C8)cycloalkyl, (C1-C6)alkoxy, —[C(R6)2]r—, —O[C(R6)2]r—, oxo, hydroxyl, halo, —C(O)R7, —R10, and —CO(O)R2;
• R16 is independently selected from the group consisting of —H, oxo, halo, hydroxyl, (C1-C6)alkyl, (C1-C6)alkoxy, (C3-C8)cycloalkyl, —R6(R9)q, —OR6(R9)q, —N(R4)2, —(CH2)r-heterocyclyl, —C(O)OH, —C(O)NH2, —R5(R9)q, —OR5(R9)q, nitro, —SO2R6, —C(O)R10, and —CO(O)R4;
• m and n in each instance are independently 0, 1, 2, 3, or 4;
• p is independently 0, 1, 2, 3, or 4;
• and
• r and q in each instance are independently 0, 1, 2, 3, or 4.

A compound having the structure of Formula I:

• or a pharmaceutically acceptable salt thereof, wherein:
• A is
• L1 and L2 are both (—CH2—);
• Q is —C(═O)—;
• W is O;
• R1 is —H;
• R2 is selected from the group consisting of —H, (C1-C6)alkyl, —(C1-C6)alkyl-OR4, —(C1-C6)alkyl-O—(C1-C6)alkyl, —C(O)R5, and —(CH2)rNR7R8;
• R3 is selected from the group consisting of —H, (C1-C12)alkyl, —NR1R2, —OR5,
• wherein:
• X is a monocyclic or bicyclic (C5-C14)aryl,
• Y is selected from a monocyclic or bicyclic (C2-C9)heterocyclyl or monocyclic or bicyclic (C2-C9)heteroaryl, each having one to three heteroatoms selected from S, N or O, and
• Z is a monocyclic or bicyclic (C3-C8)cycloalkyl;
• R4 is selected from the group consisting of —H and (C1-C6)alkyl;
• R5 is selected from the group consisting of (C1-C6)alkyl, —(CH2)rNR7R8, and —(CH2)rOR7;
• R6 and R6′ are independently selected from the group consisting of —H, (C1-C6)alkyl, (C3-C8)cycloalkyl, (C1-C6)alkoxy, haloalkyl, —(CH2)rNR7R8, —C(O)OH, and —C(O)NH2;
• R7 and R8 are independently selected from the group consisting of —H, (C1-C6)alkyl, (C3-C8)cycloalkyl, —NR14R15, and —C(O)CH3;
• R9 is halo;
• R10 is —N(R16)2;
• R11, R12, and R13 are independently selected from the group consisting of oxo, hydroxyl, halo, (C1-C6)alkoxy, —R6(R9)q, —OR6(R9)q, nitro, —SO2R6, (C1-C6)alkyl, —C(O)R10, —R4YR6, —CO(O)R4, and —CO(O)R5;
• R14 and R15 are independently selected from the group consisting of —H, (C1—C—6)alkyl, (C3-C8)cycloalkyl, (C1-C6)alkoxy, —[C(R6)2]r—, —O[C(R6)2]r—, oxo, hydroxyl, halo, —C(O)R7, —R10, and —CO(O)R2;
• R16 is independently selected from the group consisting of —H, oxo, halo, hydroxyl, (C1-C6)alkyl, (C1-C6)alkoxy, (C3-C8)cycloalkyl, —R6(R9)q, —OR6(R9)q, —N(R4)2, —(CH2)r-heterocyclyl, —C(O)OH, —C(O)NH2, —R5(R9)q, —OR5(R9)q, nitro, —SO2R6, —C(O)R10, and —CO(O)R4;
• m and n in each instance are independently 0, 1, or 2;
• p is independently 0, 1, or 2;
• and
• r and q in each instance are independently 0, 1, 2, or 3.

A compound having the structure of Formula I:

• or a pharmaceutically acceptable salt thereof, wherein:
• A is
• L1 and L2 are both (—CH2—);
• Q is —C(═O)—;
• W is O;
• R1 is —H;
• R2 is selected from the group consisting of —H, (C1-C6)alkyl, —C(O)R5, and —(CH2)rNR7R8;
• R3 is
• wherein X is a monocyclic or bicyclic (C5-C14)aryl;
• R4 is selected from the group consisting of —H and (C1-C6)alkyl;
• R5 is selected from the group consisting of (C1-C6)alkyl, —(CH2)rNR7R8, and —(CH2)rOR7;
• R6 is selected from the group consisting of —H, (C1-C6)alkyl, (C3-C8)cycloalkyl, (C1-C6)alkoxy, haloalkyl, —(CH2)rNR7R8, —C(O)OH, and —C(O)NH2;
• R7 and R8 are independently selected from the group consisting of —H, (C1-C6)alkyl, (C3-C8)cycloalkyl, —NR14R15, and —C(O)CH3;
• R9 is halo;
• R10 is —N(R16)2;
• R11, R12, and R13 are independently selected from the group consisting of oxo, hydroxyl, halo, (C1-C6)alkoxy, —R6(R9)q, —OR6(R9)q, nitro, —SO2R6, (C1-C6)alkyl, —C(O)R10, —CO(O)R4, and —CO(O)R5;
• R14 and R15 are independently selected from the group consisting of —H, (C1—C—6)alkyl, (C3-C8)cycloalkyl, (C1-C6)alkoxy, —[C(R6)2]r—, —O[C(R6)2]r—, oxo, hydroxyl, halo, —C(O)R7, —R10, and —CO(O)R2;
• R16 is independently selected from the group consisting of —H, oxo, halo, hydroxyl, (C1-C6)alkyl, (C1-C6)alkoxy, (C3-C8)cycloalkyl, —R6(R9)q, —OR6(R9)q, —N(R4)2, —(CH2)r-heterocyclyl, —C(O)OH, —C(O)NH2, —R5(R9)q, —OR5(R9)q, nitro, —SO2R6, —C(O)R10, and —CO(O)R4;
• m and n in each instance are independently 0, 1, or 2;
• p is independently 0, 1, or 2;
• and
• r and q in each instance are independently 0, 1, 2, or 3.

A compound having the structure of Formula I:

• or a pharmaceutically acceptable salt thereof, wherein:
• A is
• L1 and L2 are both (—CH2—);
• Q is —C(═O)—;
• W is O;
• R1 is —H;
• R2 is —(CH2)rNR7R8;
• R3 is
• wherein X is phenyl;
• R7 and R8 are independently selected from the group consisting of —H and methyl;
• R9 is selected from the group consisting of chloro, bromo, and fluoro;
• R11 is selected from the group consisting of chloro, bromo, and fluoro;
• m is independently 0, 1, or 2;
• and
• r is independently 1, 2, or 3.

A compound having the structure of Formula (II):

• or a pharmaceutically acceptable salt thereof, wherein:
• A is
• L1 and L2 are independently selected from a bond or [C(R6R6′)]q;
• each instance of Q is independently selected from—CH2— or —C(═O)—;
• W is selected from a bond or O;
• R1 is selected from the group consisting of —H, (C1-C12)alkyl, —C(O)R5, —CH2—O—(C1-C6)alkyl, 2-tetrahydro-2H-pyran, and
• R2 is selected from the group consisting of —H, —(C1-C6)alkyl-OR4, —(C1-C6)alkyl-O—(C1-C6)alkyl, —C(O)R5, —(CH2)rNR7R8, and —(CH2)rN+(R4)3, wherein when W is O, R1 and R2 can optionally be taken together with the O and N to which they are respectively joined to form a 4 to 8 membered heterocyclyl ring, wherein the heterocyclyl ring may be optionally substituted by one to two R11 groups;
• R3 is selected from the group consisting of —H, (C1-C12)alkyl, —NR1R2, —OR5,
• wherein:
• X is a monocyclic or bicyclic (C6-C1a)aryl,
• Y is selected from a monocyclic or bicyclic (C2-C6)heterocyclyl or monocyclic or bicyclic (C2-C6)heteroaryl, each having one to three heteroatoms selected from S, N or O, and
• Z is a monocyclic or bicyclic (C3-C8)cycloalkyl;
• R2 and R3 can optionally be taken together with the nitrogen and L2 to which they are respectively joined to form a 4 to 8 membered heterocyclyl ring wherein the heterocyclyl ring may be optionally substituted by one to two R11 groups;
• R4 is selected from the group consisting of —H and (C1-C6)alkyl;
• R5 is selected from the group consisting of —H, (C1-C6)alkyl, —R3, —(CH2)rNR7R8, and —(CH2)rOR7.
• R6 and R6′ are independently selected from the group consisting of —H, (C1-C6)alkyl, (C3-C8)cycloalkyl, (C1-C6)alkoxy, haloalkyl, —Y, —(CH2)rNR7R8, —C(O)OH, and —C(O)NH2, wherein the R6 and R6′ groups can optionally be taken together with the carbon to which they are joined to form a 3 to 8 membered cycloalkyl ring, and wherein the cycloalkyl ring may be optionally substituted by one to three R11 groups;
• R7 and R8 are independently selected from the group consisting of —H, (C1-C6)alkyl, (C3-C8)cycloalkyl, -Q-aryl-(R4)n, —NR14R15, —C(O)CH3, wherein R7 and R8 can optionally be taken together with the nitrogen to which they are joined to form a 4 to 8 membered heterocyclyl or heteroaryl ring containing one to three heteroatoms selected from —NR5—, —O—, —S—, —S(O)—, or —SO2—, wherein the heterocyclyl or heteroaryl ring may be optionally substituted by one to three R11 groups;
• R9 is halo;
• R10 is —N(R16)2;
• R11, R12, and R13 are independently selected from the group consisting of oxo, hydroxyl, halo, (C1-C6)alkoxy, —R6(R9)q, —OR6(R9)q, nitro, —SO2R6, (C1-C6)alkyl, —C(O)R10, —R4YR6, —CO(O)R4, and —CO(O)R5, wherein any two R11, R12 or R13 groups can optionally join to form a 3 to 8 membered cycloalkyl, aryl, heterocyclyl or heteroaryl ring, wherein the heterocyclyl or heteroaryl ring may contain one to three heteroatoms selected from —NR5—, —O—, —S—, —S(O)—, or —SO2—, and wherein the cycloalkyl, aryl, heterocyclyl or heteroaryl ring may be optionally substituted by one to three R16 groups;
• R14 and R15 are independently selected from the group consisting of —H, (C1—C—6)alkyl, (C3-C8)cycloalkyl, (C1-C6)alkoxy, —[C(R6)2]r—, —O[C(R6)2]r—, oxo, hydroxyl, halo, —C(O)R7, —R10, and —CO(O)R2, wherein R14 and R15 can optionally be taken together with the carbon to which they are joined to form a 3 to 8 membered cycloalkyl ring or 4 to 8 membered heterocyclyl ring containing one to three heteroatoms selected from —NR5—, —O—, —S—, —S(O)—, or —SO2—, wherein the cycloalkyl ring or heterocyclyl ring may be optionally substituted by one to three R16 groups;
• R16 is independently selected from the group consisting of —H, halo, oxo, hydroxyl, (C1-C6)alkyl, (C1-C6)alkoxy, (C3-C8)cycloalkyl, —R6(R9)q, —OR6(R9)q, —N(R4)2, —(CH2)r-heterocyclyl, —C(O)OH, —C(O)NH2, —R5(R9)q, —OR5(R9)q, nitro, —SO2R6, —C(O)R10, and —CO(O)R4;
• m and n in each instance are independently 0, 1, 2, 3, or 4;
• p is independently 0, 1, 2, 3, or 4;
• and
• r and q in each instance are independently 0, 1, 2, 3, or 4.

A compound having the structure of Formula (II):

• or a pharmaceutically acceptable salt thereof, wherein:
• A is
• L1 and L2 are [C(R6R6′)]q;
• each instance of Q is independently selected from—CH2— or —C(═O)—;
• W is selected from a bond or O;
• R1 is selected from the group consisting of —H, (C1-C6)alkyl, —C(O)R4, and
• R2 is selected from the group consisting of —H, (C1-C6)alkyl, —(C1-C6)alkyl-OR4, —(C1-C6)alkyl-O—(C1-C6)alkyl, —C(O)R5, —(CH2)rNR7R8, and —(CH2)rN+(R4)3;
• R3 is selected from the group consisting of —H, (C1-C12)alkyl, —NR1R2, —OR5,
• wherein:
• X is a monocyclic or bicyclic (C5-C14)aryl,
• Y is selected from a monocyclic or bicyclic (C2-C9)heterocyclyl or monocyclic or bicyclic (C2-C9)heteroaryl, each having one to three heteroatoms selected from S, N or O, and
• Z is a monocyclic or bicyclic (C3-C8)cycloalkyl;
• R4 is selected from the group consisting of —H and (C1-C6)alkyl;
• R5 is selected from the group consisting of (C1-C6)alkyl, —(CH2)rNR7R8, and —(CH2)rOR7;
• R6 and R6′ are independently selected from the group consisting of —H, (C1-C6)alkyl, (C3-C8)cycloalkyl, (C1-C6)alkoxy, haloalkyl, —(CH2)rNR7R8, —C(O)OH, and —C(O)NH2, wherein the R6 and R6′ groups can optionally be taken together with the carbon to which they are joined to form a 3 to 8 membered cycloalkyl ring, and wherein the cycloalkyl ring may be optionally substituted by one to three R11 groups;
• R7 and R8 are independently selected from the group consisting of —H, (C1-C6)alkyl, (C3-C8)cycloalkyl, —NR14R15, and —C(O)CH3;
• R9 is halo;
• R10 is —N(R16)2;
• R11, R12, and R13 are independently selected from the group consisting of oxo, hydroxyl, halo, (C1-C6)alkoxy, —R6(R9)q, —OR6(R9)q, nitro, —SO2R6, (C1-C6)alkyl, —C(O)R10, —R4YR6, —CO(O)R4, and —CO(O)R6;
• R14 and R15 are independently selected from the group consisting of —H, (C1—C—6)alkyl, (C3-C8)cycloalkyl, (C1-C6)alkoxy, —[C(R6)2]r—, —O[C(R6)2]r—, oxo, hydroxyl, halo, —C(O)R7, —R10, and —CO(O)R2;
• R16 is independently selected from the group consisting of —H, oxo, halo, hydroxyl, (C1-C6)alkyl, (C1-C6)alkoxy, (C3-C8)cycloalkyl, —R6(R9)q, —OR6(R9)q, —N(R4)2, —(CH2)r-heterocyclyl, —C(O)OH, —C(O)NH2, —R5(R9)q, —OR5(R9)q, nitro, —SO2R6, —C(O)R10, and —CO(O)R4;
• m and n in each instance are independently 0, 1, 2, 3, or 4;
• p is independently 0, 1, 2, 3, or 4;
• and
• r and q in each instance are independently 0, 1, 2, 3, or 4.

A compound having the structure of Formula (II):

• or a pharmaceutically acceptable salt thereof, wherein:
• A is
• L1 and L2 are both (—CH2—);
• Q is —C(═O)—;
• W is O;
• R1 is —H;
• R2 is selected from the group consisting of —H, (C1-C6)alkyl, —C(O)R5, and —(CH2)rNR7R8;
• R3 is
• wherein X is a monocyclic or bicyclic (C5-C14)aryl;
• R4 is selected from the group consisting of —H and (C1-C6)alkyl;
• R5 is selected from the group consisting of (C1-C6)alkyl, —(CH2)rNR7R8, and —(CH2)rOR7;
• R6 is selected from the group consisting of —H, (C1-C6)alkyl, (C3-C8)cycloalkyl, (C1-C6)alkoxy, haloalkyl, —(CH2)rNR7R8, —C(O)OH, and —C(O)NH2;
• R7 and R8 are independently selected from the group consisting of —H, (C1-C6)alkyl, (C3-C8)cycloalkyl, —NR14R15, and —C(O)CH3;
• R9 is halo;
• R10 is —N(R16)2;
• R11, R12, and R13 are independently selected from the group consisting of oxo, hydroxyl, halo, (C1-C6)alkoxy, —R6(R9)q, —OR6(R9)q, nitro, —SO2R6, (C1-C6)alkyl, —C(O)R10, —CO(O)R4, and —CO(O)R5;
• R14 and R15 are independently selected from the group consisting of —H, (C1-—C—6)alkyl, (C3-C8)cycloalkyl, (C1-C6)alkoxy, —[C(R6)2]r—, —O[C(R6)2]r—, oxo, hydroxyl, halo, —C(O)R7, —R10, and —CO(O)R2;
• R16 is independently selected from the group consisting of —H, oxo, halo, hydroxyl, (C1-C6)alkyl, (C1-C6)alkoxy, (C3-C8)cycloalkyl, —R6(R9)q, —OR6(R9)q, —N(R4)2, —(CH2)r-heterocycle, —C(O)OH, —C(O)NH2, —R5(R9)q, —OR5(R9)q, nitro, —SO2R6, —C(O)R10, and —CO(O)R4;
• m and n in each instance are independently 0, 1, or 2;
• p is independently 0, 1, or 2;
• and
• r and q in each instance are independently 0, 1, 2, or 3.

A compound having the structure of Formula (II):

• or a pharmaceutically acceptable salt thereof, wherein:
• A is
• L1 and L2 are both (—CH2—);
• Q is —C(═O)—;
• W is O;
• R1 is —H;
• R2 is —(CH2)rNR7R8;
• R3 is
• wherein X is phenyl;
• R7 and R8 are independently selected from the group consisting of —H and methyl;
• R9 is selected from the group consisting of chloro, bromo, and fluoro;
• R11 is selected from the group consisting of chloro, bromo, and fluoro;
• m is 0, 1, or 2;
• and
• r is 1, 2, or 3.

A compound or a pharmaceutically acceptable salt thereof selected from the group consisting of:

• Parent Structure
• Chemical Name
• 4-[(1R)-1- [(1R,2R,5R,10S,13R,14R,17S,19R)- 17-[(3-carboxy-3,3- dimethylpropanoyl)oxy]- 1,2,14,18,18-pentamethyl-7-oxo- 8-(propan-2-yl)pentacyclo [11.8.0.0{circumflex over ( )}{1,10}.0{circumflex over ( )}{5,9}.0{circumflex over ( )} {14, 19}]henicos-8-en-5-yl]-2- {[(4- chlorophenyl)methyl]amino}ethoxy]- 2,2-dimethyl-4-oxobutanoic acid
• 4-[(1R)-1- [(1R,2R,5R,10S,13R,14R,17S,19R)- 17-[(3-carboxy-3,3- dimethylpropanoyl)oxy]- 1,2,14,18,18-pentamethyl-7-oxo- 8-(propan-2-yl)pentacyclo [11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )} {14,19}]henicos-8-en-5-yl]-2- {[(4-chlorophenyl)methyl][2- (dimethylamino)ethyl]amino}eth- oxy]-2,2-dimethyl-4-oxobutanoic acid
• 4-[(1S)-1- [(1R,2R,5R,10S,13R,14R,17S,19R)- 17-[(3-carboxy-3,3- dimethylpropanyl)oxy]- 1,2,14,18,18-pentamethyl-7-oxo- 8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-5-yl]-2- {[(4- chlorophenyl)methyl]amino}ethoxy]- 2,2-dimethyl-4-oxobutanoic acid
• 4-[(1S)-1- [(1R,2R,5R,10S,13R,14R,17S,19R)- 17-[(3-carboxy-3,3- dimethylpropanyl)oxy]- 1,2,14,18,18-pentamethyl-7-oxo- 8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-5-yl]-2- {[(4-chlorophenyl)methyl][2- (dimethylamino)ethyl]amino}eth- oxy]-2,2-dimethyl-4-oxobutanoic acid
• 4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-(2-{[(4- chlorophenyl)methyl]amino}ethyl)- 1,2,14,18,18-pentamethyl-7-oxo- 8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )} {14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
• 4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-[2-(benzylamino)ethyl]- 1,2,14,18,18-pentamethyl-7-oxo- 8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
• 4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-(2-{[(3- chlorophenyl)methyl]amino}ethyl)- 1,2,14,18,18-pentamethyl-7-oxo- 8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy]-2,2-dimethyl-4-oxobutanoic acid
• 4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-(2-{[(3-chloro-2- fluorophenyl)methyl]amino}ethyl)- 1,2,14,18,18-pentamethyl-7-oxo- 8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
• 4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-(2-{[1-(4- chlorophenyl)cyclopropyl]amino}eth- yl)-1,2,14,18,18-pentamethyl-7- oxo-8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
• 4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-(2-{[(4- chlorophenyl)methyl][2- (dimethylamino)ethyl]amino}ethyl)- 1,2,14,18,18-pentamethyl-7-oxo- 8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
• 4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-(2-{[1-(4- chlorophenyl)cyclopropyl][2- (dimethylamino)ethyl]amino}ethyl)- 1,2,14,18,18-pentamethyl-7-oxo- 8-(propan-2- y)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
• 4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-(2-{[(4- chlorophenyl)methyl](methyl)amino} ethyl)-1,2,14,18,18-pentamethyl- 7-oxo-8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
• 4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-(2-{N-[(4- chlorophenyl)methyl]acetamido}eth- yl)-1,2,14,18,18-pentamethyl-7- oxo-8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
• 4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-[(1R)-2-{[(4- chlorophenyl)methyl]amino}-1- hydroxyethyl]-1,2,14,18,18- pentamethyl-7-oxo-8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2.10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
• 4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-[(1S)-2-{[(4- chlorophenyl)methyl]amino}-1- hydroxyethyl]-1,2,14,18,18- pentamethyl-7-oxo-8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
• 4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-[(1S)-2-{[(4- chlorophenyl)methyl]amino}-1- hydroxyethyl]-1,2,14,18,18- pentamethyl-7-oxo-8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
• 4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-[(1R)-1-(acetyloxy)-2-{[(4- chlorophenyl)methyl]amino}ethyl]- 1,2,14,18,18-pentamethyl-7-oxo- 8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
• 4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-[(1R)-2-{[(4- chlorophenyl)methyl][2- (dimethylamino)ethyl]amino}-1- hydroxyethyl]-1,2,14,18,18- pentamethyl-7-oxo-8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
• 4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-[(1S)-2-{[(4- chlorophenyl)methyl][2- (dimethylamino)ethyl]amino}-1- hydroxyethyl]-1,2,14,18,18- pentamethyl-7-oxo-8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
• 4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-[(1S)-1-(acetyloxy)-2-{[(4- chlorophenyl)methyl][2- (dimethylamino)ethyl]amino}ethyl]- 1,2,14,18,18-pentamethyl-7-oxo- 8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
• 4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-[(1R)-1-(acetyloxy)-2-{[(4- chlorophenyl)methyl][2- (dimethylamino)ethyl]amino}ethyl]- 1,2,14,18,18-pentamethyl-7-oxo- 8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
• 5- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-[(1R)-2-{[(4- chlorophenyl)methyl][2- (dimethylamino)ethyl]amino}-1- hydroxyethyl]-1,2,14,18,18- pentamethyl-7-oxo-8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-3,3-dimethyl-5- oxopentanoic acid
• 5- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-[(1S)-2-{[(4- chlorophenyl)methyl][2- (dimethylamino)ethyl]amino}-1- hydroxyethyl]-1,2,14,18,18- pentamethyl-7-oxo-8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-3,3-dimethyl-5- oxopentanoic acid
• 4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-[(1S)-2-{[(2- chlorophenyl)methyl]amino}-1- hydroxyethyl]-1,2,14,18,18- pentamethyl-7-oxo-8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
• 4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-[(1R)-2-{[(2- chlorophenyl)methyl]amino}-1- hydroxyethyl]-1,2,14,18,18- pentamethyl-7-oxo-8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
• 4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-[(1S)-1-(acetyloxy)-2-{[(4- fluorophenyl)methyl]amino}ethyl]- 1,2,14,18,18-pentamethyl-7-oxo- 8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
• 4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-[(1R)-1-(acetyloxy)-2-{[(4- fluorophenyl)methyl]amino}ethyl]- 1,2,14,18,18-pentamethyl-7-oxo- 8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
• 4- (((3aR,5aR,5bR,7aR,9S,11aR,11bR, 13aS)-3a-((S)-1-acetoxy-2-((4- fluorobenzyl)(methyl)amino)ethyl)- 1-isopropyl-5a,5b,8,8,11a- pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,11,11a, 11b,12,13,13a-octadecahydro- 2H-cyclopenta[a]chrysen-9- yl)oxy)-2,2-dimethyl-4-oxobutanoic acid
• 4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-[(1S)-2-{[(4- chlorophenyl)methyl](methyl)amino}- 1-hydroxyethyl]-1,2,14,18,18- pentamethyl-7-oxo-8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
• 4- (((3aR,5aR,5bR,7aR,9S,11aR,11bR, 13aS)-3a-((R)-1-Acetoxy-2-((4- chlorobenzyl)(methyl)amino)ethyl)- 1-isopropyl-5a,5b,8,8,11a- pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,11,11a, 11b,12,13,13a-octadecahydro- 2H-cyclopenta[a]chrysen-9- yl)oxy)-2,2-dimethyl-4-oxobutanoic acid
• 4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-[(1R)-2-{[(4- chlorophenyl)methyl](methyl)amino}- 1-hydroxyethyl]-1,2,14,18,18- pentamethyl-7-oxo-8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
• 4- (((3aR,5aR,5bR,7aR,9S,11aR,11bR, 13aS)-3a-((S)-1-Acetoxy-2-(N- (4-chlorobenzyl)acetamido)ethyl)- 1-isopropyl-5a,5b,8,8,11a- pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,11,11a, 11b,12,13,13a-octadecahydro- 2H-cyclopenta[a]chrysen-9- yl)oxy)-2,2-dimethyl-4-oxobutanoic acid
• 4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-[(1S)-2-{N-[(4- chlorophenyl)methyl]acetamido}- 1-hydroxyethyl]-1,2,14,18,18- pentamethyl-7-oxo-8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
• 4- (((3aR,5aR,5bR,7aR,9S,11aR,11bR, 13aS)-3a-((S)-2-(N-(4- Chlorobenzyl)acetamido)-1- hydroxyethyl)-1-isopropyl- 5a,5b,8,8,11a-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,11,11a, 11b,12,13,13a-octadecahydro- 2H-cyclopenta[a]chrysen-9- yl)oxy)-2,2-dimethyl-4-oxobutanoic acid
• 4- (((3aR,5aR,5bR,7aR,9S,11aR,11bR, 13aS)-3a-((R)-2-(N-(4- Chlorobenzyl)acetamido)-1- hydroxyethyl)-1-isopropyl- 5a,5b,8,8,11a-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,11,11a, 11b,12,13,13a-octadecahydro- 2H-cyclopenta[a]chrysen-9- yl)oxy)-2,2-dimethyl-4-oxobutanoic acid
• 4- (((3aR,5aR,5bR,7aR,9S,11aR,11bR, 13aS)-3a-((S)-2-(N-(2- Chlorobenzyl)acetamido)-1- hydroxyethyl)-1-isopropyl- 5a,5b,8,8,11a-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,11,11a, 11b,12,13,13a-octadecahydro- 2H-cyclopenta[a]chrysen-9- yl)oxy)-2,2-dimethyl-4-oxobutanoic acid
• 4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-[(1S)-1-(acetyloxy)-2-{[(2- chlorophenyl)methyl][2- (dimethylamino)ethyl]amino}ethyl]- 1,2,14,18,18-pentamethyl-7-oxo- 8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
• 4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-[(1S)-2-{[(3- chlorophenyl)methyl]amino}-1- hydroxyethyl]-1,2,14,18,18- pentamethyl-7-oxo-8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
• 4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-[(1R)-2-{[(3- chlorophenyl)methyl]amino}-1- hydroxyethyl]-1,2,14,18,18- pentamethyl-7-oxo-8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
• 4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-[(1S)-2-{[(3- chlorophenyl)methyl][2- (dimethylamino)ethyl]amino}-1- hydroxyethyl]-1,2,14,18,18- pentamethyl-7-oxo-8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
• 4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-[(1R)-2-{[(3- chlorophenyl)methyl][2- (dimethylamino)ethyl]amino}-1- hydroxyethyl]-1,2,14,18,18- pentamethyl-7-oxo-8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
• 4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-[(1S)-1-(acetyloxy)-2-{[(3- chlorophenyl)methyl]amino}ethyl]- 1,2,14,18,18-pentamethyl-7-oxo- 8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
• 4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-[(1R)-1-(acetyloxy)-2-{[(3- chlorophenyl)methyl]amino}ethyl]- 1,2,14,18,18-pentamethyl-7-oxo- 8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14.19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
• 4- (((3aR,5aR,5bR,7aR,9S,11aR,11bR, 13aS)-3a-((S)-1-acetoxy-2-((3- chlorobenzyl)(2- (dimethylamino)ethyl)amino)ethyl)- 1-isopropyl-5a,5b,8,8,11a- pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,11,11a, 11b,12,13,13a-octadecahydro- 2H-cyclopenta[a]chrysen-9- yl)oxy)-2,2-dimethyl-4-osobutanoic acid
• 4- (((3aR,5aR,5bR,7aR,9S,11aR,11bR, 13aS)-3a-((R)-1-acetoxy-2-((3- chlorobenzyl)(2- (dimethylamino)ethyl)amino)ethyl)- 1-isopropyl-5a,5b,8,8,11a- pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,11,11a, 11b,12,13,13a-octadecahydro- 2H-cyclopenta[a]chrysen-9- yl)oxy)-2,2-dimethyl-4-oxobutanoic acid
• 4- (((3aR,5aR,5bR,7aR,9S,11aR,11bR, 13aS)-3a-((R)-2-((3- chlorobenzyl)(ethyl)amino)-1- hydroxyethyl)-1-isopropyl- 5a,5b,8,8,11a-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,11,11a, 11b,12,13,13a-octadecahydro- 2H-cyclopenta[a]chrysen-9- yl)oxy)-2,2-dimethyl-4-oxobutanoic acid
• 4- (((3aR,5aR,5bR,7aR,9S,11aR,11bR, 13aS)-3a-((S)-2-((3- Chlorobenzyl)(2- (dimethylamino)ethyl)amino)-1- hydroxyethyl)-1-isopropyl- 5a,5b,8,8,11a-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,11,11a, 11b,12,13,13a-octadecahydro- 2H-cyclopenta[a]chrysen-9- yl)oxy)-2,2-dimethyl-4-oxobutanoic acid
• 4- (((3aR,5aR,5bR,7aR,9S,11aR, 11bR,13aS)-3a-((R)-2-((3- Chlorobenzyl)(2- (dimethylamino)ethyl)amino)-1- hydroxyethyl)-1-isopropyl- 5a,5b,8,8,11a-pentamethyl-2- oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,11, 11a,11b,12,13,13a- octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)- 2,2-dimethyl-4-oxobutanoic acid.
• 4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-[(1R)-2-{N-[(3- chlorophenyl)methyl]acetamido)- 1-hydroxyethyl]-1,2,14,18,18- pentamethyl-7-oxo-8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
• 4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-[(1S)-2-{N-[(3- chlorophenyl)methyl]acetamido}- 1-hydroxyethyl]-1,2,14,18,18- pentamethyl-7-oxo-8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
• 4- (((3aR,5aR,5bR,7aR,9S,11aR,11bR, 13aS)-3a-((R)-1-acetoxy-2-((2- chlorobenzyl)(2- (dimethylamino)ethyl)amino)ethyl)- 1-isopropyl-5a,5b,8,8,11a- pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,11,11a, 11b,12,13,13a-octadecahydro- 2H-cyclopenta[a]chrysen-9- yl)oxy)-2,2-dimethyl-4-oxobutanoic acid
• 4- (((3aR,5aR,5bR,7aR,9S,11aR,11bR, 13aS)-3a-((R)-2-((2- chlorobenzyl)(ethyl)amino)-1- hydroxyethyl)-1-isopropyl- 5a,5b,8,8,11a-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,11,11a, 11b,12,13,13a-octadecahydro- 2H-cyclopenta[a]chrysen-9- yl)oxy)-2,2-dimethyl-4-oxobutanoic acid
• 4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-[(1R)-2-{[(2- chlorophenyl)methyl][2- (dimethylamino)ethyl]amino}-1- hydroxyethyl]-1,2,14,18,18- pentamethyl-7-oxo-8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
• 4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-[(1S)-2-{[(2- chlorophenyl)methyl][2- (dimethylamino)ethyl]amino}-1- hydroxyethyl]-1,2,14,18,18- pentamethyl-7-oxo-8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
• 4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-[(1R)-1-(acetyloxy)-2- (benzylamino)ethyl]-1,2,14,18,18- pentamethyl-7-oxo-8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
• 4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-[(1S)-1-(acetyloxy)2- (benzylamino)ethyl]-1,2,14,18,18- pentamethyl-7-oxo-8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
• 4- (((3aR,5aR,5bR,7aR,9S,11aR,11bR, 13aS)-3a-((R)-2-((3-Chloro-2- fluorobenzyl)amino)-1- hydroxyethyl)-1-isopropyl- 5a,5b,8,8,11a-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,11,11a, 11b,12,13,13a-octadecahydro- 2H-cylcopenta[a]chrysen-9- yl)oxy)-2,2-dimethyl-4-oxobutanoic acid
• 4- (((3aR,5aR,5bR,7aR,9S,11aR,11bR, 13aS)-3a-((S)-2-((3-chloro-2- fluorobenzyl)amino)-1- hydroxyethyl)-1-isopropyl- 5a,5b,8,8,11a-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,11,11a, 11b,12,13,13a-octadecahydro- 2H-cyclopenta[a]chrysen-9- yl)oxy)-2,2-dimethyl-4-oxobutanoic acid.
• 4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-[(1R)-2-{[(3-chloro-2- fluorophenyl)methyl][2- (dimethylamino)ethyl]amino}-1- hydroxyethyl]-1,2,14,18,18- pentamethyl-7-oxo-8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
• 4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-[(1S)-2-{[(3-chloro-2- fluorophenyl)methyl][2- (dimethylamino)ethyl]amino}-1- hydroxyethyl]-1,2,14,18,18- pentamethyl-7-oxo-8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
• 4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-[(1R)-1-hydroxy-2-[(propan- 2-yl)amino]ethyl]-1,2,14,18,18- pentamethyl-7-oxo-8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
• 4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-[(1R)-2-(cyclohexylamino)-1- hydroxyethyl]-1,2,14,18,18- pentamethyl-7-oxo-8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
• 4- {[(1R,2R,5S,10S,13R,14R,17S,19R)- 5-[1-hydroxy-2-(4- methylpiperazin-1-yl)ethyl]- 1,2,14,18,18-pentamethyl-8- (propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
• 4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-(2-{[(4- chlorophenyl)methyl]amino}ethyl)- 1,2,14,18,18-pentamethyl-8- (propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
• 4- {[(1R,2R,5S,10S,13R,14R,17S,19R)- 5-[(1S)-2-{[(4- chlorophenyl)methyl]amino}-1- hydroxyethyl]-1,2,14,18,18- pentamethyl-8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
• 4- {[(1R,2R,5S,10S,13R,14R,17S,19R)- 5-[(1S)-2- [(cyclohexylmethyl)amino]-1- hydroxyethyl]-1,2,14,18,18- pentamethyl-8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
• 4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-[(1S)-2-(cyclohexylamino)-1- hydroxyethyl]-1,2,14,18,18- pentamethyl-7-oxo-8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
• 4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-[(1R)-1-hydroxy-2-(1,2,3,4- tetrahydroisoquinolin-2-yl)ethyl]- 1,2,14,18,18-pentamethyl-7-oxo- 8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
• 4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-[(1S)-1-hydroxy-2-(1,2,3,4- tetrahydroisoquinolin-2-yl)ethyl]- 1,2,14,18,18-pentamethyl-7-oxo- 8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
• 4- {[(1R,2R,10S,13R,14R,17S,19R)- 5-[(5S)-3-[1-(5-chloropyrimidin-2- yl)cyclopropyl]-2-oxo-1,3- oxazolidin-5-yl]-1,2,14,18,18- pentamethyl-7-oxo-8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
• 4- {[(1R,2R,10S,13R,14R,17S,19R)- 5-[(5R)-3-[1-(5-chloropyrimidin-2- yl)cyclopropyl]-2-oxo-1,3- oxazolidin-5-yl]-1,2,14,18,18- pentamethyl-7-oxo-8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
• 5- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-[(1S)-2-{[(4- chlorophenyl)methyl]amino}-1- hydroxyethyl]-1,2,14,18,18- pentamethyl-7-oxo-8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-3,3-dimethyl-5- oxopentanoic acid
• 4- (((3aR,5aR,5bR,7aR,9S,11aR,11bR, 13aS)-3a-((R)-2-(3,4- dihydroisoquinolin-2(1H)-yl)-1- hydroxyethyl)-1-isopropyl- 5a,5b,8,8,11a-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,11,11a, 11b,12,13,13a-octadecahydro- 2H-cyclopenta[a]chrysen-9- yl)oxy)-2,2-dimethyl-4-oxobutanoic acid
• 4- (((3aR,5aR,5bR,7aR,9S,11aR,11bR, 13aS)-3a-((S)-2-(3,4- dihydroisoquinolin-2(1H)-yl)-1- hydorxyethyl)-1-isopropyl- 5a,5b,8,8,11a-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,11,11a, 11b,12,13,13a-octadecahydro- 2H-cyclopenta[a]chrysen-9- yl)oxy)-2,2-dimethyl-4-oxobutanoic acid.
• 4- (((3aS,5aR,5bR,7aR,9S,11aR,11bR, 13aS)-3a-((R)-1-hydroxy-2-(4- methylpiperazin-1-yl)ethyl)-1- isopropyl-5a,5b,8,8,11a- pentamethyl- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,11,11a, 11b,12,13,13a-octadecahydro- 2H-cyclopenta[a]chrysen-9- yl)oxy)-2,2-dimethyl-4-oxobutanoic acid.
• 4- (((3aR,5aR,5bR,7aR,9S,11aR,11bR, 13aS)-3a-(2-((4- chlorobenzyl)amino)ethyl)-1- isopropyl-5a,5b,8,8,11a- pentamethyl- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,11,11a, 11b,12,13,13a-octadecahydro- 2H-cyclopenta[a]chrysen-9- yl)oxy)-2,2-dimethyl-4-oxobutanoic acid.
• 4- (((3aS,5aR,5bR,7aR,9S,11aR,11bR, 13aS)-3a-((S)-2- ((cyclohexylmethyl)amino)-1- hydroxyethyl)-1-isopropyl- 5a,5b,8,8,11a-pentamethyl- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,11,11a, 11b,12,13,13a-octadecahydro- 2H-cyclopenta[a]chrysen-9- yl)oxy)-2,2-dimethyl-4-oxobutanoic acid.
• 4- (((3aR,5aR,5bR,7aR,9S,11aR,11bR, 13aS)-3a-((S)-2- (cyclohexylamino)-1- hydroxyethyl)-1-isopropyl- 5a,5b,8,8,11a-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,11,11a, 11b,12,13,13a-octadecahydro- 2H-cyclopenta[a]chrysen-9- yl)oxy)-2,2-dimethyl-4-oxobutanoic acid
• 4- (((3aR,5aR,5bR,7aR,9S,11aR,11bR, 13aS)-3a-((S)-2-(benzyl(2- (dimethylamino)ethyl)amino)-1- hydroxyethyl)-1-isopropyl- 5a,5b,8,8,11a-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,11,11a, 11b,12,13,13a-octadecahydro- 2H-cyclopenta[a]chrysen-9- yl)oxy)-2,2-dimethyl-4-oxobutanoic acid
• 4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-[(1S)-1-(acetyloxy)-2-{[2- (dimethylamino)ethyl][(4- fluorophenyl)methyl]amino}ethyl]- 1,2,14,18,18-pentamethyl-7-oxo- 8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
• 4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-[(1R)-1-(acetyloxy)-2-{[2- (dimethylamino)ethyl][(4- fluorophenyl)methyl]amino}ethyl]- 1,2,14,18,18-pentamethyl-7-oxo- 8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
• 5- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-[(1R)-2-{[(4- chlorophenyl)methyl]amino}-1- hydroxyethyl]-1,2,14,18,18- pentamethyl-7-oxo-8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-3,3-dimethyl-5- oxopentanoic acid
• 5- (((3aR,5aR,5bR,7aR,9S,11aR,11bR, 13aS)-3a-((S)-2-((4- chlorobenzyl)amino)-1- hydroxyethyl)-1-isopropyl- 5a,5b,8,8,11a-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,11,11a, 11b,12,13,13a-octadecahydro- 2H-cyclopenta[a]chrysen-9- yl)oxy)-3,3-dimethyl-5- oxopentanoic acid
• 4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-[(1S)-2-{[(2,4- dichlorophenyl)methyl][2- (dimethylamino)ethyl]amino}-1- hydroxyethyl]-1,2,14,18,18- pentamethyl-7-oxo-8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
• 4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-[(1R)-2-{benzyl[2- (dimethylamino)ethyl]amino}-1- hydroxyethyl]-1,2,14,18,18- pentamethyl-7-oxo-8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
• 4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-[(1R)-2-{[2- (dimethylamino)ethyl][(4- fluorophenyl)methyl]amino}-1- hydroxyethyl]-1,2,14,18,18- pentamethyl-7-oxo-8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
• 4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-[(1R)-2-{[(4- fluorophenyl)methyl]amino}-1- hydroxyethyl]-1,2,14,18,18- pentamethyl-7-oxo-8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
• 4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-[(1S)-2-{[2- (dimethylamino)ethyl][(4- fluorophenyl)methyl]amino}-1- hydroxyethyl]-1,2,14,18,18- pentamethyl-7-oxo-8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
• 4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-[(1S)-2-{[(4- fluorophenyl)methyl]amino}-1- hydroxyethyl]-1,2,14,18,18- pentamethyl-7-oxo-8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
• 4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-[(1R)-2-{[(2,4- dichlorophenyl)methyl][2- (dimethylamino)ethyl]amino}-1- hydroxyethyl]-1,2,14,18,18- pentamethyl-7-oxo-8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
• 4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-[(1R)-2-[1-(4-chlorophenyl)- N-[2- (dimethylamino)ethyl]formamido]- 1-hydroxyethyl]-1,2,14,18,18- pentamethyl-7-oxo-8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
• 4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 5-(2-{[(2- chlorophenyl)methyl]amino}ethyl)- 1,2,14,18,18-pentamethyl-7-oxo- 8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}-2,2-dimethyl-4-oxobutanoic acid
• 2,2-dimethyl-4-oxo-4- {[(1R,2R,5R,10S,13R,14R,17S,19R)- 1,2,14,18,18-pentamethyl-7- oxo-5-[2-(phenylformamido)ethyl]- 8-(propan-2- yl)pentacyclo[11.8.0.0{circumflex over ( )}{2,10}.0{circumflex over ( )}{5, 9}.0{circumflex over ( )}{14,19}]henicos-8-en-17- yl]oxy}butanoic acid

A process for preparing a compound of Formula (I) having the structure:

• comprising the steps of:
• (1) saponifying a compound having the structure:
• in the presence of a first metal catalyst, in order to provide a compound having the structure:
• (2) reacting the compound product of Step (1), with a compound having the structure:
• in the presence of an acid chloride and a tertiary amine in order to provide a compound having the structure:
• (3) reacting nitromethane with the compound product of Step (2) in the presence of a chiral ligand, an optional base, and a second metal catalyst in order to provide a compound having the structure:
• (4) reducing the compound product of Step (3), in the presence of a third metal catalyst and hydrogen gas in order to provide a compound having the structure:
• (5) reacting p-chlorobenzaldehyde with the compound product of Step (4), in the presence of a metal hydride, to provide a compound having the structure:
• (6) acidifying the compound product of Step (5), in the presence of an acid in order to provide the compound having the structure:
• (7) reacting the compound product of Step (6) with a compound having the structure according to Formula III:
• wherein A1 is either optionally absent or is selected from the group consisting —H, methyl, and ethyl;
• and A2 is selected from the group consisting of —H, methoxy, ethoxy, hydroxyl, and —SO3−Na+;
• while in the presence of a metal hydride in order to provide the compound having the structure:

A process for preparing a compound having the structure:

• comprising the steps of:
• (1) saponifying a compound having the structure:
• in the presence of a first metal catalyst, in order to provide a compound having the structure:
• (2) reacting the compound product of Step (1), with a compound having the structure:
• in the presence of an acid chloride and a tertiary amine in order to provide a compound having the structure:
• (3) reacting nitromethane with the compound product of Step (2) in the presence of a chiral ligand and a base and a second metal catalyst in order to provide a compound having the structure:
• (4) reducing the compound product of Step (3), in the presence of a third metal catalyst and hydrogen gas in order to provide a compound having the structure:
• (5) reacting p-chlorobenzaldehyde with the compound product of Step (4), in the presence of a metal hydride and a tertiary amine, to provide a compound having the structure:
• (6) reacting the compound product of Step (5) with a compound having the structure according to Formula III:
• wherein A1 is either optionally absent or is selected from the group consisting —H, methyl, and ethyl;
• and A2 is selected from the group consisting of —H, methoxy, ethoxy, hydroxyl, and —SO3−Na+;
• while in the presence of a metal hydride in order to provide the compound having the structure:
• (7) acidifying the compound product of Step (6), in the presence of an acid in order to provide the compound having the structure:

A process for preparing a compound having the structure:

• comprising the steps of:
• (1) reacting a compound having the structure:
• with a compound having the structure according to Formula III:
• wherein A1 is either optionally absent or is selected from the group consisting —H, methyl, and ethyl;
• and A2 is selected from the group consisting of —H, methoxy, ethoxy, hydroxyl, and —SO3−Na+;
• while in the presence of a metal hydride in order to provide the compound having the structure:

A process for preparing a compound having the structure:

• comprising the steps of:
• (1) reacting a compound having the structure:
• with a compound having the structure:
• in the presence of an acid chloride and a tertiary amine in order to provide the computer having the structure: